CA2967894C — N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors
Assigned to Kalvista Pharmaceuticals Ltd · Expires 2024-01-30 · 2y expired
What this patent protects
The present invention provides compounds of formula (l): (see formula I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and meth…
USPTO Abstract
The present invention provides compounds of formula (l): (see formula I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds.
Drugs covered by this patent
- Ekterly (SEBETRALSTAT) · Kalvista
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.